NewsMV

argenx agrees to buy Forte Biosciences for $2.2 billion, adding anti-CD122 antibody to immunology pipeline

8/15/2026

The $2.2 billion cash bid for Forte Biosciences, Inc. (NASDAQ: FBRX) puts argenx SE (NASDAQ: ARGX) in focus as the acquirer's next pipeline move.

argenx agreed to pay $77 a share, a roughly 40% premium to Forte's Friday close, adding FB102, an experimental first-in-class anti-CD122 antibody, to its immunology portfolio.

Both boards have approved the deal, which the companies expect to close in Q3 2026.

The numbers FBRX shares soared as much as 42% to $77.86 in premarket trading, essentially matching the offer price, a sign the market is confident the deal closes.